People over the age of 50 are the fastest growing population in the world, creating both opportunities and challenges for the global economy and the health-care system. The long-lived industry, which provides products and services to people over the age of 50, is becoming a multi-trillion dollar new industry. Currently, in the UK alone, the longevity industry includes 260 companies, 250 investors, 10 non-profit organisations and 10 research laboratories.
Figure 1: End-to-end pipeline stoducts for the Longevity AI Alliance Research Center, a precision analytical framework developed for precision medicine and longevity diagnosis, prognosis
Over the next decade, the government’s longevity policy and changes in the financial sector will change society. Even small but meaningful results in longevity will have a huge multiplier effect on society. Extending human health life by just one year will reduce the suffering of tens of millions of people and improve the quality of life for billions of people.
Although artificial intelligence (AI) has more potential to increase health and longevity in the short term than other sectors, its use in longevity industries remains weak. AI has great potential to accelerate the implementation of longevity research and development. To address this problem, the Ageing Research Centre at King’s College (Ark) has partnered with the Biogerology Research Foundation, Deep Knowledge Ventures and other organisations to form the Longevity AI Alliance at King’s College London.
The new alliance will leverage King’s College’s world-leading research in genetics, AI and ageing research to develop advanced personalized consumption and patient care programs. The alliance will also help accelerate progress in longevity by drawing on the concerns of academia and industry about preventive and personalized physical and mental health and financial well-being. The establishment of the King’s College AI Longevity Alliance and the AI Longevity Accelerator has the potential to help the UK become the world’s leading AI Longevity Research Centre and create opportunities for significant advances in longevity research that will benefit people around the world.
Over the next few years, the Longevity AI Alliance plans to expand to include research centers in Switzerland, Israel, Singapore and the United States. This collaboration involves the complex approach of applying advanced AI to longevity solutions and the development of advanced frameworks and technologies, including innovative applications that provide life data to insurance companies, pension funds, healthcare companies, and government agencies. These new technologies and tools are at the forefront of the emerging longevity financial industry, providing practical applications for preventive medicine and precision health.
The Longevity AI Alliance will be a leading research and development center and industry academic hot spot for personalized, personalized diagnostics, prediction and treatment driven by advanced AI. This represents a paradigm shift from treatment to prevention, and a new frontier, from precision medicine to precision health, making the UK a global hub for applying AI to longevity and precision health.
The Longevity AI Alliance plans to devote resources to research and development in other scientific fields, such as the latest developments and innovations in microbial diagnosis and treatment, especially advanced cosmetics. The alliance’s goal is to identify new biomarkers of longevity and healthy aging, accelerate the diagnosis of age-related health decline, and develop personalized physical, mental and financial health to better implement and promote effective healthy and long-lived lifestyles, such as changing patterns of sleep, nutrition, physical activity, environmental exposure and financial planning.
The Longevity AI Alliance will use the complex and multidimensional analysis framework developed by Aging Analytics Agency to conduct industry benchmarks at precision health and personalized preventive medicine clinics to build the ideal diagnostic, predictive and therapeutic channels using state-of-the-art existing methods and technologies. The alliance will develop a comprehensive cloud computing platform to develop “minimally feasible” and “most comprehensive” biomarker panels for aging, create ecosystems that inspire the participation of doctors, clinics, data providers, AI companies, and business partners, and enable proven Experimental aging biomarkers can be efficiently and simply commercialized and clinically implemented as a framework for extending the UK’s healthy life expectancy goals.
Figure 3: This mind map provides an overview of the UK’s longevity industry, including 260 companies, 250 investors, 10 non-profit organizations and 10 research labs
King’s College London is the first logical perfection of the Longevity AI Alliance, as they combine AI with longevity resources, departments and technologies. King’s College is also an ideal location for the AI Alliance because it has dedicated departments and resources that can be used for both AI and longevity research. In addition, the Institute of Advanced Arts is ideally located in London for cross-industry and research and development collaboration. The Longevity AI Alliance is currently designing complementary AI Financial Health Alliance, which aims to use financial and behavioural data to develop products and services that enable British citizens to maintain financial stability and mental health during long periods of long and healthy life.
Currently, there are only three centers in the world actively working to apply AI to precision health to achieve a healthy and long life. These include the Buck Institute for Aging in the United States, Y Combinator in the United States, and the AI-PHI Institute for Predicted Health at the University of Hawaii Cancer Center. Of these, only AI-PHI has been truly successful in practice. Now that the Longevity AI Alliance has been established at King’s College London, the UK can immediately leverage its existing resources, including the very developed AI industry, and its strong reputation for industry, academic and government collaboration initiatives, to become the world’s number one hub for applying AI to longevity and precision health.
Currently, there are four major healthcare AI centres in the UK’s major industry, academic and metropolitan centres, but none of them pay special attention to longevity, precision health and preventive medicine. While these centres are a precedent and proof of concept for the feasibility of aI Longevity Centre, they do not adequately meet the UK’s need for leading AI Longevity Research and Development Centres. These centers should be able to develop leading solutions, products, and services that leverage the power of AI to implement practical products, services, and solutions to extend the healthy lives of citizens.
By 2020, with several key development milestones to come, the Longevity AI Alliance plans to launch an AI Longevity Accelerator program as a much-needed bridge between start-ups focused on longevity research and drug development and major UK investors. Although the UK’s AI and Longevity industry ecosystem is well developed, the number of longevity start-ups with AI as the main means of in-house research and development is relatively small.
The potential impact of synergies between the two sectors is enormous. The UK Government attaches great importance to the development of a separate industries, AI and Longevity, both of which are listed as major strategic challenges for the four major industries. However, by combining AI and longevity vertical markets in a unique and integrated manner, the UK can take advantage of the country’s strengths in these sectors to reach its full potential.
King’s College’s AI Longevity Accelerator aims to develop an infrastructure to promote investment and development in the AI Longevity sector and to provide a level of funding for longevity start-ups. Start-ups selected to the accelerator will also receive mentors and incubation resources, as well as a global network of experts in scientific research and development, business development and investment relationships. AI Accelerator will also provide start-ups with the tools they need to grow, expand and grow during their work, and will provide them with the capabilities they need to further develop through late-stage venture capital and government grants.
It turns out that longevity companies that can deliver real results could be the next Google, while the investment firms that invest in them could be tomorrow’s SoftBank and Vision funds.